title: [Long-term results of orthotopic liver transplantation during the cyclosporin era. 393 orthotopic liver transplantations accomplished in 313 consecutive patients at the Pittsburgh Transplantation Center].
abstract: During the cyclosporine era 1980-1984, 393 consecutive orthotopic liver transplantations (OLT) were performed in 313 patients at the University of Pittsburgh. This paper analyses the long-term results in this group of patients who have been followed-up for a minimum of three years. The results of OLT for different indications are discussed. The five-year survival rates after OLT for metabolic diseases, biliary atresia, primary biliary cirrhosis, posthepatic cirrhosis and primary hepatobiliary cancer are 75%, 68%, 60%, 58.9%, 53.2% and 23.8%, respectively. Recurrence of the primary disease after OLT is rare for benign diseases but rather frequent for malignant ones. The incidence of retransplantation for delayed rejection and for extrahepatic complications is discussed. The quality of life for most of the long-term survivors is good. Because of its good long-term results, OLT should become the therapy of choice in a lot of acute and chronic hepatopathies.
authors: J
authors: J
authors: Lerut
authors: A C
authors: AC
authors: Stieber
authors: L
authors: L
authors: Makowka
authors: C O
authors: CO
authors: Esquivel
authors: S
authors: S
authors: Iwatsuki
authors: R D
authors: RD
authors: Gordon
authors: T E
authors: TE
authors: Starzl
mesh_terms: D003524:Cyclosporins / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000187:drug effects; D006801:Humans; D008107:Liver Diseases / Q000601:surgery*; D016031:Liver Transplantation; D008875:Middle Aged; D010414:Pennsylvania; D011183:Postoperative Complications / Q000401:mortality*; D015996:Survival Rate
chemical_list: D003524:Cyclosporins
vernacular_title: Résultats à long terme de la transplantation hépatique orthotopique durant l'ère de la cyclosporine. 393 transplantations hépatiques orthotopiques réalisées chez 313 patients consécutifs au centre de transplantation de Pittsburgh.